The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database

Edwards, C.; Arden, N K; Fisher, David J.; Saperia, James; Reading, Isabel; Staa, Tjeerd van; Cooper, Cyrus

doi:10.1093/rheumatology/kei024

Cited by 59 publications

(51 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results from this study are supported by similar quantitative and qualitative fi ndings exploring disparities in care access to services and the consequences to the patient (Albers et al, 1999;Baker and Graham, 2001;Barrett et al, 2000;Edwards et al, 2005;Lapsley and Groves, 2004;Hallert et al, 2005;Hulsemann et al, 2005;Ryan, et al, 2003;Simpson et al, 2005). Individuals themselves fail to seek medical advice when they experience joint pain, possibly refl ecting the lay perspectives that 'nothing that can be done for Delivering high-quality, transparent and equitable care remains a constant challenge in healthcare provision, and clinicians should be mindful that specifi c targets and initiatives to improve care may not always bring the desired benefi ts or reveal the true experience of those using the services.…”

Section: Discussionsupporting

confidence: 76%

Exploring the healthcare journey of patients with rheumatoid arthritis: A mapping project – implications for practice

Oliver

2008

Musculoskeletal Care

View full text Add to dashboard Cite

This unique mapping approach used qualitative research and process mapping to compare patient experiences against recognized standards and guidelines. These twenty-two stories reveal important insights into the challenges experienced in negotiating these healthcare journeys and the impact upon the individual as a result of variances in standards of care received. The participants in this study were chiefly self-motivated, informed and articulate, and did not reflect the broad ethnic, social or cultural diversity in the UK. Limitations must also be considered in relation to perceptions and recall of participants over a three-year period, as these may have altered over time and illness experience.

show abstract

Section: Discussionsupporting

confidence: 76%

Exploring the healthcare journey of patients with rheumatoid arthritis: A mapping project – implications for practice

Oliver

2008

Musculoskeletal Care

View full text Add to dashboard Cite

show abstract

“…18 Inclusion is based on registration with a contributing general practice, rather than consultations, and there is no requirement that patients be actively receiving treatment. Data are stored using Oxford Medical Information System (OXMIS) or Read codes for diseases that are cross-referenced to the International Classification of Diseases (ICD-9); 19 with OXMIS usage primarily restricted to the period prior to the introduction of Read codes in 1997. The quality of entered data is continuously monitored by the Medicines and Healthcare products Regulatory Agency, with practices failing to adhere to established standards excluded from participation.…”

Section: Design and Methodsmentioning

confidence: 99%

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

Sarpatwari¹,

Bennett²,

Logie³

et al. 2010

Haematologica

203

157

View full text Add to dashboard Cite

BackgroundThe risk of thromboembolic events in adults with primary immune thrombocytopenia has been little investigated despite findings of increased susceptibility in other thrombocytopenic autoimmune conditions. The objective of this study was to evaluate the risk of thromboembolic events among adult patients with and without primary immune thrombocytopenia in the UK General Practice Research Database. Design and MethodsUsing the General Practice Research Database, 1,070 adults (≥18 years) with coded records for primary immune thrombocytopenia first referenced between January 1 st 1992 and November 30 th 2007, and having at least one year pre-diagnosis and three months post-diagnosis medical history were matched (1:4 ratio) with 4,280 primary immune thrombocytopenia disease free patients by age, gender, primary care practice, and pre-diagnosis observation time. The baseline prevalence and incidence rate of thromboembolic events were quantified, with comparative risk modelled by Cox's proportional hazards regression. ResultsOver a median 47.6 months of follow-up (range: 3.0-192.5 months), adjusted hazard ratios of 1.58 (95% CI, 1.01-2.48), 1.37 (95% CI, 0.94-2.00), and 1.41 (95% CI, 1.04-1.91) were found for venous, arterial, and combined (arterial and venous) thromboembolic events, respectively, when comparing the primary immune thrombocytopenia cohort with the primary immune thrombocytopenia disease free cohort. Further event categorization revealed an elevated incidence rate for each occurring venous thromboembolic subtype among the adult patients with primary immune thrombocytopenia. ConclusionsPatients with primary immune thrombocytopenia are at increased risk for venous thromboembolic events compared with patients without primary immune thrombocytopenia. Database. Haematologica 2010;95:1167-1175. doi:10.3324/haematol.2009 This is an open-access paper. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

show abstract

“…Unfortunately, discontinuation of therapy is common with these agents; for example, the proportion of people still taking gold after 5 years is 20%, sulfasalazine 35% and methotrexate 57%. 34 Such data highlight the limitations of the available agents; that is, relatively short-term drug 'survival' for a disease with a lifelong course.…”

Section: Goals Of Managementmentioning

confidence: 99%

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

Chen

Jobanputra

Barton

et al. 2006

Health Technol Assess

322

261

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: P Jobanputra is a Consultant Rheumatologist and a member of the British Society for Rheumatology. He has received funding for educational purposes from Abbott and Wyeth and has been entertained by manufacturers of all three TNF inhibitors. He has been involved in research studies of adalimumab and etanercept for rheumatoid arthritis and his department has received funding from Wyeth and Abbott for these studies. HTA Published November 2006This report should be referenced as follows:Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of ...

show abstract

The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database

Cited by 59 publications

References 19 publications

Exploring the healthcare journey of patients with rheumatoid arthritis: A mapping project – implications for practice

Exploring the healthcare journey of patients with rheumatoid arthritis: A mapping project – implications for practice

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

Contact Info

Product

Resources

About